💡 Did you know?
The BSE, founded in 1875, is Asia's oldest stock exchange — it started under a banyan tree on Dalal Street, where the bronze bull stands today.
History
The BSE, founded in 1875, is Asia's oldest stock exchange — it started under a banyan tree on Dalal Street, where the bronze bull stands today.
The BSE, founded in 1875, is Asia's oldest stock exchange — it started under a banyan tree on Dalal Street, where the bronze bull stands today.
Gufic Biosciences Limited is an India-based company, which is engaged in the manufacturing and marketing of active pharmaceutical ingredients, generic pharmaceuticals and related services. The Company operates in the pharmaceutical segment. It has pharmaceutical products…
Weekly engine runs — movement reflects the numbers, not analyst opinion.
A weak, stagnant business, priced for perfection.
Gufic Biosciences is scored on the pharma / healthcare framework. It keeps a slim 6.8% of every rupee of sales as net profit. Cash conversion lags the reported profit (CFO/PAT 0.70×) — worth a closer look. Free cash flow is worth about 0.3% of its market value.
Over the last 2 years revenue compounded at 8%/yr and profit at -14%/yr. Book value has grown 12%/yr. Return on equity is a modest 9.7%. In the latest quarter profit grew 2% versus the prior quarter.
At 67× earnings, the stock sits at the 98th percentile of its own 2.6-year range — the expensive end of where it has historically traded. Today's price already implies ~24%/yr earnings growth sustained for a decade — a demanding bar. The books come through clean — a forensic grade of A, and Altman puts distress risk in the safe zone.
A plain-English restatement of the figures on this page — rules-based, for education and research context, not investment advice or a recommendation.
| Ratio | Company | Sector | Read |
|---|---|---|---|
| P/E | 58.67 | — | — |
| P/B | 6.48 | 4.1 | worse |
| EV/EBITDA | 28.08 | 19.33 | worse |
| ROE | 9.66 | — | — |
| ROCE | 11.45 | 14.41 | worse |
| ROA | 5.47 | 1.64 | better |
| Quick Ratio | 0.92 | 4.8 | worse |
| Peer | P/E | P/B | ROE |
|---|---|---|---|
| Sun Pharmaceutical Industries | 40.6 | 5.0 | 13.8% |
| Divis Laboratories | 93.5 | 16.3 | 15.3% |
| Torrent Pharmaceuticals | 85.9 | 9.8 | 11.4% |
Revenue has grown every year across all 3 financial years shown. 8% CAGR — growing but slowly. Growth is accelerating — latest year outpaced the prior year's rate.
Revenue is outpacing profit (8% vs -14%) — costs are rising faster than the top line.
Operating margin has compressed from 14% to 9% — costs or competition are eating into profitability. Margins have declined for 2 consecutive years — watch for a structural cost problem.
ROE at 10% — modest; the capital isn't working hard. Capital efficiency declining — ROE down 7pp.
EPS dropped in the latest year despite possible profit changes — dilution or a profit dip could be at play. -14% EPS CAGR — this is the rate at which each share's claim on earnings is compounding.
1 of 3 years had negative operating cash flow — profitability on paper may not translate to cash. Heavy investing spend every year, but operations generate enough to cover it — the business self-funds its growth. Raising capital despite positive cash flow — could signal expansion plans or opportunistic fundraising.
When operating cash keeps pace with reported profit, earnings are cash-backed; a persistent shortfall is a quality flag.
Revenue broadly flat QoQ — stable but not accelerating. Run-rate stepping up — recent quarters average 9% above earlier ones.
How today's P/E compares to the stock's own historical range. Dashed line = the 2.6y median.
Promoters hold 72.5% — heavily owner-operated with strong skin in the game.
Produced by a rules-based engine over licensed exchange fundamentals — every sentence above is derived from the numbers shown, no analyst or AI opinion involved. Education and research context, not investment advice. We are not SEBI-registered as an Investment Adviser or Research Analyst.